Preclinical data suggest that combined MEK and PI3K inhibition will be required to enhance and prolong the anti-tumor activity of MEK inhibitors in KRAS-mutant colon cancers with alterations in the PI3K pathway. Here, PIK3CA is linked to neoplasm.